Life Sciences Tools and Services
Company Overview of SeraCare Life Sciences, Inc.
SeraCare Life Sciences, Inc. provides products and services to facilitate the discovery, development, and production of human and animal diagnostics, and therapeutics. The company’s Diagnostic and Biopharmaceutical Products segment offers controls and panels for the evaluation and quality control of infectious disease tests in clinical laboratories, blood banks, and in vitro diagnostic (IVD) manufacturing; and reagents and bioprocessing products for use in the discovery, development and manufacturing processes for drugs, vaccines, and diagnostic tests. It also provides diagnostic intermediates for use in manufacturing diagnostic test kits; cell culture additives and media that maintain viabi...
37 Birch Street
Milford, MA 01757
Founded in 1984
Key Executives for SeraCare Life Sciences, Inc.
Chief Executive Officer and President
Chief Financial Officer and Secretary
Vice President of Human Resources
Vice President of Manufacturing Operations
Compensation as of Fiscal Year 2015.
SeraCare Life Sciences, Inc. Key Developments
SeraCare Life Sciences Announces Launch of NGS Validated HIV-1 Reference Materials
Sep 23 15
SeraCare Life Sciences announced that the company's new precision medicine business unit has launched Seraseq™ HIV-1 Reference Materials; a portfolio consisting of 12 individual high-titer HIV-1 viral isolates that have been characterized by next-generation sequencing (NGS). These products are intended for use with targeted NGS assays that determine HIV-1 subtype, identify drug resistance mutations or assign viral tropism. HIV drug resistance has tremendous consequences in terms of treatment failure and overall health care costs. With increasing numbers of drug resistance mutations being characterized, Sanger sequencing-based assays have been the preferred genotyping method. However, it has been recognized that they are limited in their ability to detect critical minority variants below 20% frequency. As clinical laboratories access to NGS technology increases, so will the ability to develop assays with improved sensitivity. Reference materials with clinically actionable resistance mutations that have been characterized by NGS-methods are critical for labs developing NGS-based assays for HIV. Seraseq™ HIV-1 Reference Materials are high-titer isolates that can be used to validate new assays, compare different test results as well as monitor assay performance on an ongoing basis.
SeraCare Life Sciences, Inc. Signs Partnership Agreement with ViveBio, LLC
Jul 30 15
SeraCare Life Sciences, Inc. signed a partnership agreement with ViveBio, LLC to enable next generation preanalytic products for the in vitro diagnostics (IVD) industry. Both the entities are based in the US. Under the terms of the agreement, SeraCare and ViveBio will jointly market and sell their combined technologies into the in vitro diagnostic development market.
Seracare Life Sciences Launches Seraseq™ Solid Tumor Mutation Mix—I (AF20)
Jul 8 15
SeraCare Life Sciences announced that the company's new precision medicine business unit has launched its first product, the Seraseq™ Solid Tumor Mutation Mix—I (AF20); a biosynthetic reference material designed to evaluate the performance of next generation sequencing (NGS)-based tumor profiling assays. This product contains a mixture of mutations in key oncogenes and tumor suppressor genes and is intended as a quality material for translational and disease research testing. In addition, it permits laboratories to monitor library preparation, sequencing and variant allele detection under a given set of bioinformatics pipeline or parameters. It is currently for research use only. Clinical laboratories that have adopted next-generation sequencing for somatic mutation detection typically maintain their own pre-diluted mixtures of characterized cell-line DNA, which is labor intensive, inconsistently characterized and of unknown stability and variability. A well-designed quality control program is critical for providing reliable results obtained for unknown specimens. The use of independent reference products may provide valuable information concerning assay sensitivity and bioinformatics pipeline analysis. Seraseq™ Solid Tumor Mutation Mix is a mixture of biosynthetic target genes with specific engineered mutations in a wild-type background of well-characterized genomic DNA, and is compatible with all major cancer hotspot oncology panels and NGS platforms on the market. With a novel internal quality marker, Seraseq™ Solid Tumor Mutation Mix makes it simple to analyze and monitor potential laboratory contamination levels over time. This first version includes 26 major cancer 'hotspot' genes, all at 20% allelic frequency and quantitated using digital PCR to ensure high accuracy. It is stable for two years under recommended storage conditions, and can undergo ten freeze-thaw cycles without any degradation of performance.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|